Key Takeaways:
Embecta Corp. investors filed a securities class action after the medical device company's stock plunged 57% on a second-quarter earnings miss and a 46% cut to full-year guidance.
"The company gave investors the misleading impression that it had a reliable basis for its fiscal guidance," the complaint alleges, citing violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
The lawsuit covers shareholders who bought Embecta (NASDAQ: EMBC) common stock between Nov. 25, 2025 and May 4, 2026. On May 5, Embecta reported it failed to meet its guidance for the second quarter of fiscal 2026 and lowered its full-year outlook by 46%, largely due to weakness in pen needle sales. The company also cut its dividend by 93%. Shares fell more than 57% to $3.90 per share on the news.
The case, filed in the U.S. District Court for the Northern District of California, alleges Embecta concealed competitive threats to its pen needle business while continuously reaffirming its revenue guidance and the strength of that segment. The company, which provides insulin delivery solutions for people with diabetes, had touted its fiscal 2026 outlook during the class period, according to the complaint.
The Schall Law Firm and Robbins LLP are among the firms representing investors. Shareholders who purchased Embecta securities during the class period have until Aug. 17, 2026 to petition the court to serve as lead plaintiff.
The 57% single-day decline erased hundreds of millions of dollars in market value and pushed the stock to its lowest level since the company was spun off from Becton Dickinson in 2022. Investors will watch for any additional disclosures from Embecta regarding its competitive position in the pen needle market and whether further guidance revisions are necessary.
This article is for informational purposes only and does not constitute investment advice.
